Denne ubalance opstod, fordi patienter på deferoxamin fik tilladelse til at blive på deres før- studiedosering, selvom denne dosis var højere end den protokolspecificerede dosis.
This imbalance occurred because patients on deferoxamine were allowed to remain on their pre-study dose even if it was higher than the protocol specified dose.